$EAPH Announces Due Diligence Update

TORONTO, ON–(Marketwired – Jan 12, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces due diligence update with the disclosure of total number of plants, strains and current dispensaries being serviced.

With the company’s quest to provide as much detailed information as possible with its negotiations as previously announced, the company is pleased to share some invoices on current medicated markets dispensaries who are its current clients, this update is as promised and was following Eastons meetings with Medicated Markets and Its Master Grower over this past weekend In Toronto, Canada.

Medicated Markets possesses California Marijuana grower’s licenses and are currently growing at its two Nursery locations (20 acre’s) in City of Perris, Riverside County, California and one main growing location in Mendocino County, California with a total actual growing area of approximately 3 acres and a total plant volume of 10,000 plants. Capacity could be raised quite easily as plants require approximately 4 square feet of growing area. Each plant is expected to yield anywhere from 1 to 2 pounds of medicinal grade Marijuana.

Pictures of the mother plants that are used for cloning and copies of sales invoices for the corresponding dispensaries can be found immediately at @Medimarkets orhttps://twitter.com/medimarkets with indexing to their https://medicatedmarkets.com/ website once its delegation returns from Toronto on the 18th of January 2015.

A sampling of Current Dispensaries being serviced by growers at Medicated Markets are:

Herban Life
1820 Mentone Blvd. Suite A
Mentone, CA 92539

SBPC
154 South E. Street
San Bernadino, CA 92401

Doc Holiday’s
1366 North E. Street
San Bernadino, CA 92405

Dr. Green Thumb’s
6645 Lankershim Blvd
North Hollywood, CA 91606

1743 West foothill blvd
Upland, CA 91786

DNR
1911 Mentone Blvd
Mentone, CA 92359

A few of the medicated markets strains being grown and a few of the ones in the current seed bank with mother’s pending are as follows:

1. AK47 (mostly Sativa) AK-47 mixes Colombian, Mexican, Thai, and Afghani varieties, bringing together a complex blend of flavors and effects. While AK-47’s scent is sour and earthy, its sweet floral notes can only be fully realized in the taste.
Awards:
– 3rd place Hybrid Cup at the 2011 High Times Cannabis Cup
– 2nd place Sativa Cup at the 1999 High Times Cannabis Cup
– 2nd place Indica Cup at the 2003 High Times Cannabis Cup
– 1st place Sativa Cup at the 2010 Treating Yourself Expo

2. Chocolope (95% Sativa, 5% Indica)
Awards
– 2nd Place Sativa Cup at the 2010 High Times Cannabis Cup.
– 2nd Place Outdoor Cup at the Spannabis 2011 Champions Cup.
– 3rd Place Indoor Bio Cup at the Spannabis 2008 Champions Cup.
– 2nd Hydro Cup at the 2007 Highlife Cup.
– 2nd Place Cannabis Cup at the High Times Cannabis Cup 2007.
– High Times Strain of the Year 2007

3. Jack Herer (55% sativa hybrid) 50-70day flowering time
Awards:
Jack Herer won the 2012 Lifetime Achievement Award at the HIGH TIMES Medical Cannabis Cup in Los Angeles

Additional strains there was constant demand for

1. Bay Eleven
2. Stonehenge
3. Sour Diesel
4. Train wreck
5. Time wreck
6. Grand Daddy Purp
7. Purple Haze
8. Super Silver Haze
9. White Widow

Info From Master Grower:
For future harvests, medicated markets are moving away from growing strains that have been indigenous to the west coast for some time. Their focus will be geared toward previous Cannabis Cup winner strains and uncommon imported strains. They will command a higher price from their dispensary partners. Medicated markets recognizes the importance memories play on smoking and will concentrate on growing strains that bring nostalgia to people’s lives. They have also been working on some patentable hybrid strains, which we would love to share once that process has progressed further along.

Additional Seed Bank (pending mothers)
1. Amnesia Haze
2. Big Bud
3. Blueberry Kush
4. Super Skunk
5. Gold Leaf
6. Green Crack

Medicated Markets delegation will depart Toronto at the end of current week, January 18th 2015 with Easton Pharmaceuticals hoping to announce a finalized agreement between the two parties; at that point or shortly thereafter. At which point Grow location addresses will also be provided to the public. There are a few minor details currently discussed including co-operation with Medicated Markets and use of its Grow expertise in Easton’s Port Perry, Ontario operations that are awaiting imminent MMPR Licensure. Pictures of this facility are to be found on Easton’s web site.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
https://www.eastonpharmaceuticalsinc.com

https://ecigmarkets.com/

https://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, and are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.